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Abstract
Aims The role of non‐invasive telemedicine (TM) combining telemonitoring and teleintervention by videoconference (VC) in
patients recently admitted due to heart failure (HF) (‘vulnerable phase’ HF patients) is not well established. The aim of the
Heart failure Events reduction with Remote Monitoring and eHealth Support (HERMeS) trial is to assess the impact on clinical
outcomes of implementing a TM service based on mobile health (mHealth), which includes remote daily monitoring of biomet-
ric data and symptom reporting (telemonitoring) combined with VC structured, nurse‐based follow‐up (teleintervention). The
results will be compared with those of the comprehensive HF usual care (UC) strategy based on face‐to‐face on‐site visits at
the vulnerable post‐discharge phase.
Methods and results We designed a 24 week nationwide, multicentre, randomized, controlled, open‐label, blinded endpoint
adjudication trial to assess the effect on cardiovascular (CV) mortality and non‐fatal HF events of a TM‐based comprehensive
management programme, based on mHealth, for patients with chronic HF. Approximately 508 patients with a recent hospital
admission due to HF decompensation will be randomized (1:1) to either structured follow‐up based on face‐to‐face appoint-
ments (UC group) or the delivery of health care using TM. The primary outcome will be a composite of death from CV causes
or non‐fatal HF events (first and recurrent) at the end of a 6 month follow‐up period. Key secondary endpoints will include
components of the primary event analysis, recurrent event analysis, and patient‐reported outcomes.
Conclusions The HERMeS trial will assess the efficacy of a TM‐based follow‐up strategy for real‐world ‘vulnerable phase’ HF
patients combining telemonitoring and teleintervention.
Keywords Chronic heart failure; Telemedicine; mHealth; Outcomes research; Chronic care model; Transitional care
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Introduction
Despite the improvement in pharmacological treatment and
other non‐pharmacological approaches, heart failure (HF) re-
mains a huge public health problem in developed countries.1
Population studies have shown a rising prevalence of HF
that leads to an increase in medical resource use and
expenditure.2 A significant proportion of such health expendi-
ture is due to hospital admissions, and therefore, efforts
to improve the delivery of chronic care and avoiding
readmissions in these patients have been promoted in
recent years.3
Readmission rates due to HF are high and tend to concen-
trate in the first few months after hospitalization.4,5 For this
reason, new multidisciplinary transitional care interventions
have been focused on the so‐called ‘vulnerable phase’
that comprises the period that begins immediately after
hospital discharge and extends from 3 to 6 months during
post‐discharge follow‐up.3,6 Transitions of care in this period,
including actions such as discharge planning, drug concilia-
tion, and education, should ideally start during hospitalization
before discharge.5 Telemedicine (TM) has been proposed as
one of the key components that may help to improve out-
comes in transitional HF care programmes. Potential TM
interventions include daily control of biometric data and
symptoms (telemonitoring) and telemedical interventions
such as structured follow‐up based on telephone calls or
videoconference (VC) to provide delivery of evidence‐based
care.7,8
Trials assessing separately the efficacy of structured
follow‐up (telephone) or telemonitoring have shown mixed
results probably owing to differences in (i) the TM models
evaluated, (ii) the HF patient populations included, and (iii)
the health care contexts.7–12 All these factors may explain
why current clinical practice guidelines do not make specific
recommendations regarding the use of non‐invasive TM in
the management of patients with HF.1 Thus, the exact role
and the potential benefits of delivering HF care by means of
TM need further evaluation particularly in the setting of
new transitional care models. In these new models, delivery
of care based on the combined use of telemonitoring (to
provide early detection of worsening and enabling early pre-
ventive therapeutic interventions) and teleintervention (to
provide evidence‐based structured follow‐up by means of
VC) is an appealing approach.
We piloted this strategy in a single‐centre proof‐of‐
concept clinical trial (The insuficiència Cardíaca Optimització
Remota [iCOR] Heart Failure Remote Optimization).7 In this
small study, we demonstrated that adding a combination of
telemonitoring and teleintervention to an existing compre-
hensive HF programme reduced the risk of non‐fatal HF
events and the risk of HF and cardiovascular (CV)‐related
readmissions as compared with structured follow‐up based
on face‐to‐face appointments. These benefits were seen
across pre‐specified subgroups of patients and were accom-
panied by a reduction in hospital costs and improvement in
patient‐centred outcomes.7,13
In order to confirm the results of the iCOR study and to as-
sess the scalability of this mobile health (mHealth) based
model of care in other health care areas and settings, we de-
signed the ‘Heart failure Events reduction with Remote Mon-
itoring and eHealth Support’ (HERMeS) trial. The HERMeS
trial is a nationwide, multicentre, randomized study aimed
to assess the effect of a TM‐based comprehensive manage-
ment programme on CV mortality and non‐fatal HF events
compared with usual care (UC) in patients with chronic HF.
In this study, TM is delivered using mHealth technology that
allows the combined use of telemonitoring of signs and
symptoms and teleintervention by means of VC.
The present article provides a full description of the HER-
MeS trial design and the mHealth‐based TM platform specif-
ically designed for this study.
Study design
The HERMeS trial is a multicentre, randomized (1:1), con-
trolled, open‐label, blinded endpoint adjudication (PROBE)
investigator‐initiated study (ClinicalTrials.gov Identifier:
NCT03663907).
Patients will be recruited for 24 months in 10 centres
across Spain (Appendices S1, S2, and S3) and followed up
for a fixed period of 6 months. The study protocol was ap-
proved by the institutional review boards of the coordinating
centre (Bellvitge Biomedical Research Institute, Institut
d’Investigació Biomèdica de Bellvitge [IDIBELL], Barcelona,
Spain) and the recruiting centres. The study will be executed
in accordance with the principles of the Declaration of Hel-
sinki (1996); the International Conference on Harmonization
Good Clinical Practice; and local, national, and international
regulations, including the legal regulations about personal
data confidentiality (Organic Law 3/2018 of 5 December on
the protection of personal data and the guarantee of digital
rights and, by extension, General Data Protection Regulation
[EU] 2016/679). All enrolled patients will provide written in-
formed consent for participation in the study.
The trial was designed and will be implemented by the
HERMeS Steering Committee (Appendix S4). Safety will be re-
ported by local investigators in accordance with the current
legislation that regulates pharmacovigilance in Spain. End-
point adjudication for the components of the primary out-
come of the study will be performed by an independent
endpoint committee (clinical endpoint committee [CEC])
blinded to the group allocation and to the recruiting centre
on an ongoing basis according to the reporting of major
events (death, readmissions, and non‐fatal HF events) made
by the local investigators (Appendix S5).
Rationale and design of the HERMeS trial 4449
ESC Heart Failure 2020; 7: 4448–4457
DOI: 10.1002/ehf2.12962
Population and recruitment
The main inclusion criteria are (i) age ≥ 18 years, HF diagnosis
according to European Society of Cardiology criteria, (ii) a re-
cent hospital discharge after HF hospitalization (≤30 days),
and (iii) written informed consent to participate. Detailed in-
clusion and exclusion criteria are shown in Table 1.
Randomization and stratification
Eligible patients before discharge or attending outpatient
clinics, in a period of 30 days from discharge, will be screened
and invited to participate in the study provided they fulfil in-
clusion and exclusion criteria. Participants will be randomized
in a 1:1 ratio to control (UC arm) or intervention group (TM
arm). Randomization will be stratified at each centre and ac-
cording to the presence or absence of frailty to ensure bal-
anced assignment of frail patients to each group. For the
purpose of this study, frailty will be defined according to
the criteria specified in Table 2 in line with the definition used
in the iCOR study.7 The randomization process will be carried
out centrally by a dedicated algorithm of the Research Elec-
tronic Data Capture (REDCap®) platform.
Study assessments and follow‐up
All the patients included in the study will be followed up for
6 months (Figure 1). Briefly, patients included in the TM
arm will be telemonitored and followed up according to a
specific clinical pathway that includes pre‐planned structured
follow‐up contacts with the health care team using VC. Pa-
tients in the UC arm will be followed up according to the
UC of each recruiting centre. Because all the recruiting cen-
tres have active and mature ongoing HF programmes, no
maximum number of pre‐planned contacts has been defined,
particularly in the UC arm. Details of the TM platform and the
follow‐up strategies of the two groups will be described later.
In both groups, patients and caregivers will receive
health education to improve their self‐care behaviours. All
patients will be trained and encouraged to carry out daily
self‐monitoring of biometric data (weight, blood pressure
[BP], and heart rate [HR]) and symptom self‐monitoring in
order to detect new episodes of HF that could be managed
early with oral diuretic adjustments or intravenous diuretics
on an outpatient basis without admission. In both groups,
when an acute decompensation is suspected, nurses and
physicians will promote diuretic dose adjustments following
specific protocols and algorithms (Appendix S6) and/or ob-
tain the immediate support of an HF specialist, who will
make a decision according to the patient signs and symp-
toms (e.g. hospitalization, face‐to‐face visit, and day hospi-
tal). In case of unplanned contacts because of development
of new symptoms or abnormal biometrics, decision making
will depend on the judgement of the attending physician.
In both groups, unplanned face‐to‐face contacts could be
made if the clinical situation of the participants warrants
it. In both arms, patients and caregivers will be able to con-
tact health care professionals involved in patient care di-
rectly by telephone during working hours, depending on
the availability of each HF unit.
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
• Age ≥ 18 years
• Patients discharged from an HF hospitalization within
30 days of enrolment into the study or in the process of
discharge planning
• HF diagnosis according to ESC criteria
• Written informed consent obtained before any assessment
is performed
• Patients receiving oral standard medication for CHF
• All patients will be eligible regardless of the level of LVEF:
HFrEF, HFmrEF, and HFpEF
• Age < 18 years
• Participation in another clinical trial
• Moderate or severe cognitive impairment without a competent
caregiver
• Lack of social support
• Institutionalized patients
• Life expectancy > 1 year (excluding HF)
• Institutional‐based or end‐of‐life care
• Serious psychiatric illness
• Planned cardiac surgery
• Planned heart transplantation or LVAD implant
• Patients in haemodialysis programme
• Death before hospital discharge
• The patient is unable or unwilling to give the informed consent to
participate
• The patient is considered an unsuitable candidate for this study
according to the decision of the local investigator
• Unstable patients with signs of fluid overload or low cardiac output
CHF, chronic heart failure; ESC, European Society of Cardiology; HF, heart failure; HFmrEF, heart failure with mid‐range ejection fraction;
HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVAD, left ventricular assist de-
vice; LVEF, left ventricular ejection fraction.
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Telemedicine group: the PIRENe platform
Follow‐up and treatment of patients in the TM arm will
be based on the PIRENe platform. The PIRENe platform
(Platform for the Provision of Tele‐Intervention, Remote
Monitoring and Empowerment to people with
advanced/complex chroNic [CV] disease based on electronic
health [eHealth]) is a comprehensive solution for the care
and monitoring of chronic patients, modelled and tested in
chronic HF patients (Figure 2). This platform allows the
provision of multichannel service and monitoring of patients
through the following:
1 Patient monitoring of
a Biometric data (weight, HR, and BP);
b Symptom report: seven questions to capture the wors-
ening of the symptoms of heart disease, mainly worsen-
ing of the HF, and one question to capture general
deterioration (Table 3). The questions are posed to an-
swer ‘yes’ or ‘no’.
2 Generation and management of warning alarms notified to
the professionals assigned to each patient in case one of
the following situations occurs:
a Out‐of‐range biometric data (according to preset ranges
specified in Appendix S7).
b Any alarm symptom among the answers to the question-
naire (one ‘yes’ answer in the questionnaire generates a
warning alarm in the platform).
c Absence of biometric measurements on any given day.
Table 2 Frailty criteria to stratify the patients included in the study
before randomization
Frailty criteriaa
• Age ≥ 90 years
• Age 85–89 years needing caregiver
• Barthel index < 90 points at any age
• Pfeiffer test ≥ 3 mistakes at any age
• Patient is or will be planning a Home Care Program (ATDOM
programme)
ATDOM, (Atenció Domiciliària) home health care.
aAny participant will be considered as fragile if he or she meets at
least one of the prior criteria.
FIGURE 1 Flow chart of the study. CV, cardiovascular; HF, heart failure; PROMs, patient‐reported outcome measures; TM, telemedicine; UC, usual
care.
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This will allow medical professionals to contact the patient
proactively and thus be able to act earlier.
3 Follow‐up via teleconsultation (videoconferencing, audio
conferencing, mailing, and management of incoming and
outgoing calls) between professionals and
patients/caregivers
The platform is composed of three key technical elements:
(i) a health care web application interface for health care pro-
fessionals (PIRENe Platform website). This application is a
clinical workstation designed to store basic patient informa-
tion. It allows videoconferencing, management of agendas
(patient and health care professionals), and the specific
gateway assigned to each patient, as well as to retrieve bio-
metric values and responses to the symptoms questionnaire
to be assessed by the nursing and medical staff; and (ii) a
household patient interface (app version for smartphone
with Android operating system of the PIRENe platform). This
is the gateway to the TM platform for receiving and sending
information (4G or WiFi). By means of the designed app, pa-
tients and caregivers will manage the daily monitoring of
biometric data retrieved from peripheral devices (scale and
BP/HR monitor) by Bluetooth, and symptoms will be re-
trieved from questionnaires available in the app. Planned
VCs will also be launched through the app (4G or WiFi); and
(iii) monitoring devices: digital scale and BP/HR monitor with
Bluetooth connection provided to the patients. Linking of
data between medical devices, gateway, and the clinical
workstation will be performed according to national regula-
tions for the of handling personal data. At the beginning of
follow‐up, each patient randomized to the TM arm will be
provided with the equipment detailed in Appendix S8.
As mentioned earlier, the follow‐up of patients is based on
a standardized clinical pathway. The assessments performed
at each visit (evaluation schedule) are shown in Table 4.
Usual care group
Patients randomized to the UC arm will be followed up for
6months, with no maximum number on planned face‐to‐face
contacts, and will receive the standard of care considered UC
at each centre. As mentioned before, all participating centres
FIGURE 2 The PIRENe platform (Platform for the Provision of Tele‐Intervention, Remote Monitoring and Empowerment to people with advanced/
complex ChroNic [CV] Disease based on e‐Health).
Table 3 Daily symptom telemonitoring
Symptom report Answers
1. My feet are more swollen than usual. Yes/No
2. I feel more fatigued, tired or with a
sensation of choking.
Yes/No
3. I had bad nights because of shortness
of breath or sensation of choking.
Yes/No
4. I needed more pillows to breathe better
at night lying on my bed.
Yes/No
5. I had to sleep seated because of shortness
of breath or sensation of choking when lying
on the bed.
Yes/No
6. I felt weaker or more dizzy than usual. Yes/No
7. I had more breast pain than usual. Yes/No
8. In general, I feel worse than usual. Yes/No
4452 S. Yun et al.
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have active integrated HF programmes in place delivering (i)
nurse‐based coordination of care, (ii) education to patients
and caregivers, (iii) pro‐active up‐titration of HF
disease‐modifying drugs, (iv) cardiac rehabilitation and other
usual interventions provided in HF programmes, and (v) open
access clinics to treat HF worsening without hospital admis-
sion. The participating centres represent a wide range of HF
models deployed in different settings (tertiary, secondary,
and community hospitals and home‐based primary care
programmes), coordinated by different specialties (cardiol-
ogy, internal medicine, and primary care) in the various Span-
ish regions with differences in the organization of health care.
In both arms, unplanned contacts will be permitted in the
event of clinical deterioration.
Data collection
The medical history, relevant clinical and demographic infor-
mation, a physical examination, laboratory tests, functional,
cognitive, and socio‐family evaluation, and the technology
skills of patients included in the study (Appendix S9) will be
obtained at baseline and at the final study visit. Clinical
events will be prospectively captured by investigators and re-
ported through a dedicated formulary of the electronic case
report form. These events will be allocated and validated by
CEC members during the study. All data will be registered in
the REDCap® platform.
Outcomes and event adjudication
The primary outcome will be a composite of death from CV
causes or non‐fatal HF events (first and recurrent) at the
end of the 6 month follow‐up period as previously used in
other studies.14,15 A non‐fatal HF event is defined as a new
episode of worsening of symptoms and signs consistent with
acute decompensated HF requiring intravenous decongestive
therapy (e.g. diuretics) either on an outpatient basis (e.g.
day‐case HF hospital or at home) or in the emergency depart-
ment (<24 h), or requiring unplanned hospital admission
(>24 h) or complicating the course of a non‐CV admission.
Key secondary endpoints will include components of the
primary event analysis (all‐cause, CV and HF death, and/or
hospitalization), days spent in the hospital (length of stay
for readmission), emergency visits, patient‐reported outcome
measures such as self‐care behaviour and health‐related
quality of life (European Quality of Life 5 Dimensions), and
patient‐reported experience measures.
As stated previously, the CEC will adjudicate all the events
reported during the HERMeS trial to be used for the analyses
of the primary and secondary endpoints (Appendix S10), ac-
cording to pre‐specified criteria (Appendix S11).
Statistical methods
Sample size
According to our previous data,7 the expected event rate
for the primary endpoint (CV death or non‐fatal HF event)
in the control group would be 49% after 6 months of
follow‐up. To obtain a reduction of 25% in the rate of
the primary endpoint in the group managed with TM, and
assuming an alpha risk = 0.05 and a beta error of 20%,
we need to recruit 508 analysable patients (254 patients
in each arm). We estimate that a 25% reduction in the pri-
mary endpoint would drop the expected event rate of this
endpoint from 49% in the control group (UC) to a 36% in
the TM group. Thus, in our opinion, this reduction is clini-
cally relevant.
Analysis of primary and secondary outcomes
Details on the final statistical analyses will be defined in a
dedicated complete statistical analysis plan after the last pa-
tient’s last visit and before the database lock.
a Time to first event analysis:The incidence of events in
the two study groups (TM and UC) will be described
using Kaplan–Meier survival functions, which will be
compared using the log rank test. Additionally, we will
use Cox proportional risk regression models to obtain
the hazard ratio of each of the events under study by
comparing TM (as exposure to study) with UC as a refer-
ence group.
b Recurrent event analysis:A bivariate negative binomial
regression analysis will be performed to determine the
effect of the intervention on CV hospitalizations and
non‐fatal HF events (first and recurrent). Coefficients
from this method will be estimated by accounting for
the positive correlation among the recurrent outcome
and death as a terminal event, by linking the two simul-
taneous equations (readmission count and death) with
shared frailty.16 In addition, each patient’s follow‐up
time will be used as an offset in the models to account
for differences in the follow‐up. By using this methodol-
ogy, the potential for bias due to death as informative
censoring is minimized, an issue commonly seen in acute
HF studies. Risk estimates from this method are pre-
sented as incidence rate ratios and 95% CIs.
The subgroup analyses for the primary event will be previ-
ously specified in the final statistical analysis plan, based on
relevant clinical characteristics such as the left ventricular
ejection fraction (LVEF), age, or gender, among others. Once
defined, the interactions between the subgroups and the
type of management (TM vs. UC) in the primary event will
be evaluated.
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Discussion
The HERMeS trial is an unique clinical trial since it (i) inte-
grates mHealth as a management tool in patients with HF
combining two key elements of TM (telemonitoring and
structured teleintervention); (ii) evaluates the impact of
the simultaneous use of these two modalities of TM in the
most ‘vulnerable phase’ of patients with HF; (iii) integrates
mHealth in pre‐existing HF programmes with a high standard
of care and covering a broad range of care models and set-
tings; and (iv) includes real‐world patients in terms of co‐
morbidities, frailty, or range of LVEF.
Beyond telemonitoring and teleintervention, the PIRENe
platform allows promoting self‐care and self‐efficacy of
patients by providing them with up‐to‐date information
about the individual progression of their own biometrics
and self‐perceived health status. From our previous pilot
experience, we believe that the care delivered with the mo-
dality of TM used in the present study will translate into
an improvement of outcomes. Particularly, combining, from
one side, teleintervention by VC to deliver structured
pre‐planned interventions and, from the other side,
telemonitoring of signs and symptoms, may be an effective
strategy especially for those patients with HF in the
so‐called ‘vulnerable phase’ , the period that encompasses
discharge from an acute HF admission and the following early
post‐discharge period. Besides, from the subgroup analyses
of the iCOR study,7 we believe that the benefit will extend
to all HF patients in the ‘vulnerable phase’ regardless of
LVEF,13 presence of frailty, depressive symptoms, or co‐
morbidities. The purpose of the HERMeS trial will also include
validation of the main results of the iCOR study in a nation-
wide ‘vulnerable phase’ HF patient’s cohort and confirm the
robustness of the results among different clinical subgroups
of patients and diverse health care settings. According to
all these aspects, the HERMeS trial will address the
current gap of knowledge regarding the right strategy in the
managed care in early post‐discharge period or ‘vulnerable
phase’ in patients with HF and will allow the generalization
of the results found in the iCOR study. Additionally, it will
help to define the profile of patients that could benefit most
from a mHealth‐based management strategy combining
telemonitoring and teleintervention in integrated care
settings.
In the care process focused on transitions of care, there
are potential advantages of using a modality of TM that
combines telemonitoring and teleintervention. Firstly, it
allows remote monitoring of biometric data and/or symp-
toms to enable the early detection and monitoring of decom-
pensation and other clinical events that would otherwise lead
to readmission; secondly, it establishes a channel of commu-
nication with patients from their home to conduct structured
follow‐up after discharge, either by the means of telephone
calls or VC. These virtual pre‐planned encounters may allow
nurses educating the patient and the caregiver in order to
promote patient empowerment and adequate self‐care be-
haviours. Moreover, remote monitoring is a source of individ-
ual biometric and symptoms data that can be leveraged to
create opportunities for drug optimization, because they
may facilitate the decision‐making process of up‐titration of
HF disease‐modifying drugs in these patients.7,8 The target
population that can benefit most from this management
strategy is the one that has a higher risk of presenting new
HF (fatal or non‐fatal) events. Early detection means early
treatment, thus slowing disease progression and reducing
clinical events and health care costs.7,17,18 As previously men-
tioned, the iCOR study7 demonstrated the positive impact
of combined remote monitoring and teleintervention on
HF patients during the transition between discharge and
early post‐discharge ambulatory care. Therefore, in o ur
study, we built a mHealth platform capable of providing
the combination of these two modalities of TM during the so‐-
called ‘vulnerable phase’ of HF where most adverse events
concentrate in these patients.5
In the current health care context of aging and multiple co‐
morbidities, these models of remote care have many advan-
tages. In contrast with usual HF programme models, where
only highly selected patients are candidates to be managed
in hospital‐based units and delivery of care is based on
face‐to‐face encounters, these new remote management
transitional care models delivered using mHealth platforms
allow extending a high standard of care to real‐world patients
who are often expelled from specialized hospital care. Inter-
estingly, in our previous study, we showed that the efficacy
of TM combining telemonitoring and teleintervention was
similar in all patients regardless of age, frailty, co‐morbidities,
and ejection fraction.7,13 This approach will reduce patient in-
equalities in access to good quality of care. The organization
of care around the natural place for patients (home) by
means of TM will engage productive interactions with pri-
mary care professionals. This fact will promote a truly inte-
grated care in these patients and will raise de bar of quality
of care among primary care professionals.
The development that we propose can transform the cur-
rent management process in symptomatic patients with HF,
particularly in those in the ‘vulnerable phase’ of the disease.
This may eventually translate in new recommendations in
clinical practice guidelines regarding the use of TM in the
managed care of patients with HF and subsequently in the
design of prevention policies or procurement of public health
systems. The methods and approaches we evaluate in the
setting of HF management may find a broader application
elsewhere in cardiology and other areas of medicine involving
the management of chronic conditions. Our study may help,
through big data analysis of biometric data, to refine predic-
tion models, redesign clinical protocols, and prompt earlier
preventive interventions.19
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This project represents an important step in linking tech-
nology with clinical science and incorporates mHealth as an-
other tool for the follow‐up of patients with HF. Previous
studies have evaluated mobile technology by using it in the
form of either telephone calls or electronic messages.7,9,11,17
However, the evaluation of the efficacy of mHealth combin-
ing both remote monitoring and teleintervention by VC on
outcomes and disease progression in the ambulatory man-
agement of HF20 particularly in patients with HF in the
‘vulnerable phase’ has not previously been addressed. The
HERMeS trial will provide the adequate framework to address
this gap of knowledge.
In summary, this project has the potential for significant
advances in clinical management, resulting in direct improve-
ments to the lives of many thousands of HF patients.
Conclusions
The HERMeS trial will assess the efficacy of TM combining
telemonitoring and teleintervention in real‐world HF
patients with recent hospitalization. We believe that this
mHealth‐based strategy of delivering managed care will
translate into a significant reduction in mortality or hospital
readmissions in these high‐risk patients in the ‘vulnerable
phase’ of the disease.
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